Results of an analytical similarity test provide additional evidence in support of a biologics license application filed with the FDA by Amgen and Allergan.
An analytical similarity assessment has demonstrated that the Amgen and Allergan rituximab biosimilar candidate (ABP 798) is structurally and functionally similar to its reference biologic counterparts marketed in the United States and Europe.
Amgen, of Thousand Oaks, California, and Allergan, based in Dublin, Ireland, submitted a biologics license application to the FDA for review of ABP 798 in December 2019. ABP is a CD20-directed antibody that promotes cancer cell death through cytolysis, or excess fluid absorption. The reference product is indicated for treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
The analytical assessment evaluated the antigen binding properties of ABP 798 and demonstrated that ABP 798 has similar amino acid sequence; structure; glycan profile, which relates to pharmacodynamic and pharmacokinetic attributes; and biological activity. There were minor differences in biochemical attributes that were not considered clinically meaningful.
The authors of the study concluded that ABP 798 is “highly analytically similar” to the reference rituximab product (Rituxan [United States], MabThera [European Union]) and said the findings support use of ABP 798 in all approved indications of the reference product.
ABP 798 was developed to offer the same strength and dosage approved for reference rituximab in the United States and Europe: 10 mg/mL in 100-mg and 50-mg single-use vials for intravenous administration. The study evaluated active and inactive ingredients to assess safety, efficacy, and product quality of the biosimilar candidate.
Amgen developed the biosimilar and is collaborating with Allergan to develop and commercialize 4 oncology antibody biosimilars, including ABP 798. Allergan became a property of AbbVie in May 2020.
There are 2 rituximab biosimilars on the market in the United States currently: Ruxience (Pfizer) and Truxima (Celltrion/Teva).
Reference
Seo N, Huang Z, Kuhns S. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. Biologicals. Published online September 1, 2020. doi:10.1016/j.biologicals.2020.08.002
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.